{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreighn7a54ynekaisfozy7kxmmx2jqulq2cyqnjcsrx4ojdeixuqeze",
    "uri": "at://did:plc:eobd5mcx7ftjlptghhczesnx/app.bsky.feed.post/3mino4t2fslq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif47lvlnnokh53c6rfsv2ikaatpsu2dqzqwclgckgr3sncxxz57he"
    },
    "mimeType": "image/jpeg",
    "size": 529154
  },
  "path": "/science-tech/2026-04-04/following-the-initial-trials-in-africa-of-the-groundbreaking-drug-that-could-put-an-end-to-aids.html",
  "publishedAt": "2026-04-04T04:00:00.000Z",
  "site": "https://english.elpais.com",
  "tags": [
    "África",
    "UN",
    "Gilead Sciences",
    "Zambia",
    "Malaria",
    "Donald Trump"
  ],
  "textContent": "Eswatini, the country with the highest HIV prevalence in the world, is one of the first places to distribute lenacapavir, an injectable drug that is practically equivalent to a vaccine and with which health authorities expect to end the epidemic before 2030",
  "title": "Following the initial trials in Africa of the groundbreaking drug that could put an end to AIDS"
}